Title: Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights.
Authors: Kleiner, Galit; Ismail, Farooq; Khan, Omar; Pilieci, Christopher; Truong, Linda; Boulias, Chris
Abstract: Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.
Subjects: BOTULINUM toxin; BOTULINUM A toxins; BURDEN of care; PHYSICIAN services utilization; COGNITION disorders
Publication: Canadian Journal of Neurological Sciences, 2025, Vol 52, Issue 1, p141
ISSN: 0317-1671
Publication type: Academic Journal
DOI: 10.1017/cjn.2024.46

Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights.

Kleiner, Galit; Ismail, Farooq; Khan, Omar; Pilieci, Christopher; Truong, Linda; Boulias, Chris